Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders

A pharmaceutical composition comprising as active agent a racemate of the compound of formula I

• or pharmaceutically acceptable salts of said racemate consisting of at least 51% S-enantiomer and not more than 49% R-enantiomer in association with pharmaceutically acceptable carriers.

A package or kit comprising a pharmaceutical composition of a racemate of the compound of formula I

• or pharmaceutically acceptable salts of said racemate consisting of at least 51% S-enantiomer and not more than 49% R-enantiomer, optionally in association with pharmaceutically acceptable carriers for administration according to a method for the treatment of anxiety or of other psychiatric disorders with underlying anxiety symptomatologies in a subject in need thereof.

A pharmaceutical composition comprising as active agent a racemate of the compound of formula I

• or pharmaceutically acceptable salts of said racemate consisting of at least 51% S-enantiomer and not more than 49% R-enantiomer, optionally in association with pharmaceutically acceptable carriers.

A package or kit comprising a pharmaceutical composition of a racemate of the compound of formula I

• or pharmaceutically acceptable salts of said racemate consisting of at least 51% S-enantiomer and not more than 49% R-enantiomer optionally in association with pharmaceutically acceptable carriers for administration according to a method for the treatment affective or attention disorders in a subject in need thereof.